<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00696904</url>
  </required_header>
  <id_info>
    <org_study_id>M10-351</org_study_id>
    <nct_id>NCT00696904</nct_id>
  </id_info>
  <brief_title>Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, pharmacokinetics of ABT-333
      in healthy volunteers and the antiviral activity in HCV infected subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1, double-blind, randomized, placebo-controlled clinical trial in healthy and HCV
      genotype 1 infected adults to evaluate safety, tolerability, antiviral activity and
      pharmacokinetics of ABT-333.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of pharmacokinetic variables and mean change in HCV RNA level from baseline.</measure>
    <time_frame>approximately 1 week or less</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of safety measures, including but not limited to tabulation of adverse events, physical exam, clinical lab results (include chemistry, hematology and urine) and vital signs.</measure>
    <time_frame>approximately 1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of variance of pharmacokinetic variables for subjects fasting or nonfasting.</measure>
    <time_frame>approximately 1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volunteers, receiving 10-1200 mg ABT-333 or placebo, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HCV+ treatment-naive subjects receiving 100-300 mg ABT-333 or placebo, multi-dose, QD or BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volunteers, receiving 100 mg ABT-333, multi-dose, food effect</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-333</intervention_name>
    <description>Capsule, see arms for intervention description</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule, see arms for intervention description</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Main Selection Criteria for Healthy Volunteers:

               -  Subject has provided written consent.

               -  Subject is in general good health.

               -  If female, subject is postmenopausal.

               -  If female, subject is not pregnant and is not breast-feeding.

          -  Main Selection Criteria for HCV+ Subjects:

               -  Subject is HAV-IgM, HBsAg or HIV Ab negative.

               -  Subject is HCV genotype 1 with HCV RNA of &gt; 50,000 IU/mL.

               -  Subject is excluded if they have previously received antiviral therapy for HCV
                  infection

               -  Subjects must demonstrate chronic hepatitis C infection for at least 6 months
                  prior to study enrollment

               -  Subjects must have a prior liver biopsy with histology consistent with HCV
                  induced liver damage, and with no evidence of cirrhosis or liver pathology due to
                  any cause other than chronic HCV.

        Exclusion Criteria:

        See above for main selection criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Mensing S, Polepally AR, KÃ¶nig D, Khatri A, Liu W, Podsadecki TJ, Awni WM, Menon RM, Dutta S. Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies. AAPS J. 2016 Jan;18(1):270-80. doi: 10.1208/s12248-015-9846-1. Epub 2015 Nov 23.</citation>
    <PMID>26597291</PMID>
  </results_reference>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2008</study_first_submitted>
  <study_first_submitted_qc>June 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2008</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <name_title>Daniel Cohen, MD, Study Medical Director</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

